Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Next Previous
X
Search
Trial Profile

A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tabelecleucel (Primary)
  • Indications B-cell lymphoma; Carcinoma; Diffuse large B cell lymphoma; Haemophagocytic lymphohistiocytosis; Hodgkin's disease; Leiomyosarcoma; Lymphoproliferative disorders; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Post-transplant lymphoproliferative disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Atara Biotherapeutics

    • Most Recent Events

    • 29 Nov 2023 Results presented in an Atara Biotherapeutics media release.
    • 29 Nov 2023 According to an Atara Biotherapeutics media release, pooled analysis of four single-arm, open-label studies, (NCT04554914, NCT00002663, NCT01498484 and multicenter, expanded-access protocol NCT02822495) (n=18), will be presented as an oral session at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Annual Congress, 2023.
    • 13 Dec 2022 Results evaluating efficacy and safety of Tabelecleucel presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top